Author(s): Srinivasulu Kuraku, K. Narendra KumarReddy*, Srujan Peddi and K. Vijay Ranjan
The main objective is to formulate and evaluate the ambroxol Hcl sustained release matrix tablets for treating bronchial asthma and chronic bronchitis. In addition, the oral medication is generally considered as the first avenue investigated in the discovery and development of new drug entities and pharmaceutical formulations, mainly because of patient acceptance, convenience in and cost-effective manufacturing process. Ambroxol hydrochloride tablets were prepared by direct compression method by using hydrophilic polymer like HPMC K4M, HPMC K15M and HPMC K100M. The prepared matrix tablets were tested for evaluation parameters such as drug content, hardness, friability, weight variation, in-virto drug release and release kinetics.The formulation FS12 showed better sustained release of about 99.81% and follows Higuchi order with high regression value of 0.993 with complete drug release in 12 hrs made it to select as an optimized formulation compared with other formulations. Thus it was selected for in vivoinvestigation.